Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gains from Investment Securities for 4 consecutive years, with $269000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $269000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 9954.55% increase, with the full-year FY2024 number at $5.7 million, up 28.34% from a year prior.
  • Gains from Investment Securities was $269000.0 for Q3 2025 at Orchestra BioMed Holdings, down from $428000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.0 million in Q2 2022 to a low of -$36000.0 in Q3 2022.
  • A 4-year average of $301888.9 and a median of $269000.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 103.74% in 2024, then soared 3618.18% in 2025.
  • Orchestra BioMed Holdings' Gains from Investment Securities stood at $226000.0 in 2022, then skyrocketed by 30.09% to $294000.0 in 2023, then plummeted by 103.74% to -$11000.0 in 2024, then skyrocketed by 2545.45% to $269000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Gains from Investment Securities are $269000.0 (Q3 2025), $428000.0 (Q2 2025), and $387000.0 (Q1 2025).